argenx to Present at BofA Securities 2025 Health Care Conference

Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3] - The company collaborates with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into a portfolio of novel antibody-based medicines [3] - argenx has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, evaluating its potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines [3] Upcoming Event - Tim Van Hauwermeiren, the Chief Executive Officer of argenx, along with members of the management team, will present at the BofA Securities 2025 Health Care Conference on May 13, 2025, at 4:20 p.m. PT [1] - A live webcast of the presentation will be available on the Investors section of the argenx website, with a replay accessible for approximately 30 days following the event [2]